Dr. Thilo Enderle appointed as new Chief Executive Officer of Hit Discovery Constance GmbH Jan 10, 2019 Milan (Italy)/Constance (Germany) – Axxam announces the appointment of Dr. Thilo Enderle as Chief Executive Officer of Hit Discovery Constance (HDC), a joint venture company held by Axxam, the Centre for Drug Design and Discovery (CD3) of KU […]
Axxam SpA expands to Denmark; opens office in Copenhagen Sep 27, 2018 Axxam SpA (Milan/Italy), a privately-owned innovative Partner Research Organization (iPRO) with a strong and leading expertise for the identification and characterization of bioactive compounds, announced this month the opening of its first Scandinavian office, located in the Copenhagen Bioscience Park (COBIS) in Copenhagen,
Axxam SpA expands to Denmark; opens office in Copenhagen Read More »
Axxam SpA is a member of an international consortium for the further development of a promising drug against neuropathic pain Milan (Italy), 20 September 2018 Axxam is proud to announce its participation to a consortium of international partners, held by the Danish Hoba Therapeutics, for the further development of a promising drug against neuropathic pain.
Axxam SpA is a member of the RESOLUTE consortium Milan, 4th July 2018. Axxam is proud to announce its participation to the RESOLUTE (Research empowerment on solute carriers) consortium, a public-private research partnership supported by the Innovative Medicines Initiative (IMI), to accelerate research in the field of solute carrier (SLC) class of transporters and to
Axxam SpA is a member of the RESOLUTE consortium Read More »
Acousia Therapeutics Announces €10 Million Series B Financing to Advance its Hearing Loss Portfolio May 14th, 2018 – Milan (Italy) – Axxam is proud to announce that Acousia Therapeutics (Tubingen; Germany), a biotech company participated by Axxam and focused to develop therapies for the treatment of hearing loss, raised €10 Million in Series B Financing
Axxam S.p.A. collaborates with GenSight Biologics S.A. to support Clinical Trials of an optogenetic-based gene therapy drug for sight-threatening diseases April 24th 2018 – Milan (Italy) – Axxam S.p.A. announced today a collaboration with GenSight Biologics S.A. in the field of optogenetic gene-therapy drug development, with the goal to support GenSight effort of establishing innovative therapies
AXXAM expands its natural products service business Thursday 22nd March 2018, Milan – Axxam SpA (“AXXAM”) announces today the acquisition of all shares of IMAX Discovery GmbH (“IMAX Discovery”) held by IMD Natural Solutions GmbH (“INS”) to make IMAX Discovery a subsidiary of AXXAM. In the course of this transaction, IMAX Discovery acquired the natural
AXXAM expands its natural products service business Read More »
Axxam and Proximagen enter into a strategic collaboration for the discovery of novel molecules against targets for CNS disorders, pain and inflammation January 10th 2018 – Milan (Italy) and Cambridge (UK) – Axxam S.p.A. and Proximagen Ltd. today announced a strategic drug discovery collaboration for the identification and optimisation of small molecules as potential therapeutics in
Rewind Therapeutics, founded by Axxam and CD3, focusing on myelin-related diseases, raises €15.2 million in Series A Financing Round January 4th, 2018 – Milan (Italy) – Axxam is proud to announce that Rewind Therapeutics, a Belgian biotech company recently founded by Axxam itself and KU Leuven’s Centre for Drug Design and Discovery (CD3 – Leuven,
leadXpro and Axxam enter collaboration on a GPCR lead discovery project Milan, Italy, & Villigen, Switzerland, 1st of November 2017 – Axxam SpA and leadXpro AG announce today a collaboration for the discovery of novel small molecule lead compounds for a newly discovered GPCR involved in inflammatory processes. In the collaboration, Axxam and leadXpro will
leadXpro and Axxam enter collaboration on a GPCR lead discovery project Read More »
